In this study, both PDGCOs_1 and PDGCAs_1 were sensitive to the MET inhibitor crizotinib, likely reflecting a tumor-intrinsic sensitivity in patient 1’s epithelial cells that permitted effective drug targeting, even in the presence of stromal-mediated resistance to other agents. The gene discussed is MET; the disease is neoplasm.